About the Authors
- Indrani Rebbapragada
-
Affiliation Department of Biology, Gilead Sciences Inc., Foster City, California, USA
- Gabriel Birkus
-
Affiliation Department of Biology, Gilead Sciences Inc., Foster City, California, USA
- Jason Perry
-
Affiliation Department of Structural Chemistry Gilead Sciences Inc., Foster City, California, USA
- Weimei Xing
-
Affiliation Department of Biology, Gilead Sciences Inc., Foster City, California, USA
- HyockJoo Kwon
-
Affiliation Department of Biology, Gilead Sciences Inc., Foster City, California, USA
- Stefan Pflanz
-
* E-mail: Stefan.Pflanz@gilead.com
Affiliation Department of Biology, Gilead Sciences Inc., Foster City, California, USA
Competing Interests
All authors (IR, GB, JP, WX, HK, and SP) are employees of Gilead Sciences Inc and were recipients of salary payments, employment benefits, and company stock. GS-9620 is presently evaluated in clinical trials for possible therapeutic utility in HBV and HIV infection. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. Other declarations related to consultancy, patents, or marketed products, do not apply to the authors.
Author Contributions
Conceived and designed the experiments: IR GB JP HK SP. Performed the experiments: IR GB WX HK. Analyzed the data: IR GB SP. Contributed reagents/materials/analysis tools: GB JP WX HK. Wrote the paper: IR SP.